Reverse DCF
What growth does the market imply for THYROCARE?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
17.8% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹388
Historical Growth
14.2%
FCF Yield
2.37%
Price / FCF
42.2x
Plain English
To justify today's price of $388.15, THYROCARE.NS needs to grow its free cash flow at 17.8% per year for the next 10 years. That is 3.6% faster than its historical growth rate of 14.2%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 8.9% | ₹196 | -49.4% |
| GDP rate | 10.0% | ₹213 | -45.0% |
| Historical | 14.2% | ₹296 | -23.8% |
| Implied | 17.8% | ₹390 | +0.4% |
At Historical Growth Rate
It would take 15 years for THYROCARE to organically grow into today's price assuming its historical FCF growth of 14.2%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.